Overview
Influenzal acute upper respiratory infections (URIs) represent a significant burden in both pediatric and adult populations, often leading to substantial morbidity and healthcare utilization. These infections primarily affect the upper respiratory tract, including the nose, sinuses, pharynx, and larynx, manifesting with a constellation of symptoms that can range from mild to severe. Given their high prevalence, particularly among young children and during flu seasons, understanding the epidemiology, clinical presentation, diagnosis, and management of these infections is crucial for effective clinical practice. This guideline synthesizes evidence from recent studies to provide clinicians with a comprehensive approach to managing influenzal URIs across different age groups.
Epidemiology
Acute upper respiratory infections (URTIs) are among the most common reasons for pediatric medical consultations, accounting for over 50% of visits [PMID:34030710]. The incidence is notably higher in younger children, affecting up to 25% of infants under one year and 18% of those aged one to four years [PMID:34030710]. This high prevalence underscores the substantial clinical and economic impact of URTIs, particularly in early childhood where immature immune systems are more susceptible to viral pathogens. The frequent occurrence of these infections not only strains healthcare resources but also disrupts daily activities and school attendance, highlighting the need for effective preventive measures and targeted interventions. Additionally, seasonal variations, especially during influenza seasons, exacerbate the burden, necessitating vigilant monitoring and timely management strategies.
Clinical Presentation
The clinical presentation of influenzal URTIs can vary widely but typically includes a combination of systemic and local symptoms. Common manifestations include fever, headache, myalgia, arthralgia, malaise, and respiratory symptoms such as cough, sore throat, and nasal congestion [PMID:37937499]. The inflammatory response triggered by viral infections contributes significantly to these symptoms, often leading to substantial discomfort and functional impairment. In pediatric populations, the WURSS-K (Well-Being and Upper Respiratory Symptoms-Kids) tool provides a standardized method for assessing symptom severity and quality of life impact through a 15-item questionnaire using Likert scales [PMID:34030710]. This validated instrument facilitates objective measurement, enabling clinicians to quantify illness severity and functional impairments effectively. For adults, studies have shown that localized symptoms like sore throat can be particularly distressing, with interventions such as flurbiprofen spray demonstrating clinically meaningful relief over extended periods [PMID:29376761]. These findings underscore the importance of targeted symptom management to improve patient comfort and recovery.
Diagnosis
Diagnosing influenzal URTIs can be challenging due to overlapping symptoms with other respiratory conditions, including COVID-19. Traditional clinical evaluation often relies on symptomatology, but validated symptom scales can enhance diagnostic accuracy, especially in telemedicine settings where physical examination is limited [PMID:34030710]. The Polish version of the WURSS-K tool, for instance, has been utilized to differentiate between URTIs and COVID-19 by capturing specific symptom profiles and their impact on daily functioning [PMID:34030710]. While laboratory tests such as rapid antigen tests and PCR can confirm influenza infection, their availability and turnaround times can vary. Therefore, integrating symptom assessment tools like WURSS-K can provide valuable supplementary information, aiding in timely and accurate diagnosis and guiding appropriate management strategies.
Management
Effective management of influenzal URTIs focuses on symptom relief and supportive care, with the goal of improving patient comfort and facilitating recovery. Changes in symptom severity, as measured by tools like the WURSS-K, serve as critical indicators of treatment efficacy, allowing clinicians to quantitatively assess clinical outcomes and adjust interventions as needed [PMID:34030710]. Pharmacological interventions play a pivotal role in symptom management. For instance, flurbiprofen spray has demonstrated significant relief from sore throat symptoms, providing rapid onset and sustained efficacy over several hours [PMID:29376761]. This intervention not only addresses localized pain but also contributes to overall symptom alleviation, enhancing patient well-being. In adolescents, where psychological factors can complicate recovery, anti-inflammatory agents with analgesic and antipyretic properties, such as KLS (likely referring to a specific compound or class of drugs), offer multifaceted benefits by mitigating both physical discomfort and systemic inflammation [PMID:37937499]. Non-pharmacological approaches, including hydration, rest, and supportive care, remain foundational in managing these infections.
Special Populations
Pediatric Patients
Preschool-aged children are particularly vulnerable to URTIs due to their developing immune systems and frequent exposure to pathogens in communal settings like daycare centers [PMID:34030710]. The immature immune response in this age group often results in more frequent and severe infections. Standardized symptom assessment tools like the WURSS-K are invaluable in this population, offering a structured approach to monitor symptom progression and treatment effectiveness [PMID:34030710]. Regular use of such tools can help identify early signs of complications and guide timely interventions, thereby reducing the overall burden of illness and minimizing disruptions to daily activities and schooling.
Adolescents
Adolescents present unique challenges in the context of URTIs, primarily due to their developmental stage and psychological resilience [PMID:37937499]. Respiratory infections can exacerbate existing mental health concerns and disrupt social interactions, impacting their overall well-being. Effective management strategies must therefore address both physical symptoms and psychological support. Anti-inflammatory medications with analgesic properties, such as those highlighted in recent studies, can alleviate physical discomfort, while psychosocial support and open communication about their experiences can mitigate emotional distress. Clinicians should be vigilant in recognizing signs of prolonged illness or complications, ensuring comprehensive care that considers the holistic needs of adolescents.
Key Recommendations
References
1 Ostrzyżek-Przeździecka K, Panczyk M, Ratajczak A, Bronikowski M, Feleszko W. Validation and clinical evaluation of a Polish translation of the Wisconsin Upper Respiratory Symptom Survey for Kids (WURSS-K). Health and quality of life outcomes 2021. link 2 Marseglia GL, Ciprandi G. Clinical use of ketoprofen lysine salt: a reappraisal in adolescents with acute respiratory infections. Allergologia et immunopathologia 2023. link 3 de Looze F, Russo M, Bloch M, Montgomery B, Shephard A, DeVito R. Meaningful relief with flurbiprofen 8.75 mg spray in patients with sore throat due to upper respiratory tract infection. Pain management 2018. link